Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy
Status:
Withdrawn
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety and effectiveness of autologous human
placental-derived stem cells (HPDSC) in combination with autologous cord blood in neonates
with severe hypoxic-ischemic encephalopathy.